[HTML][HTML] Drug repurposing and human parasitic protozoan diseases
Parasitic diseases have an enormous health, social and economic impact and are a
particular problem in tropical regions of the world. Diseases caused by protozoa and …
particular problem in tropical regions of the world. Diseases caused by protozoa and …
Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives
F Alves, G Bilbe, S Blesson, V Goyal… - Clinical microbiology …, 2018 - Am Soc Microbiol
Research in visceral leishmaniasis in the last decade has been focused on how better to
use the existing medicines as monotherapy or in combination. Systematic research by …
use the existing medicines as monotherapy or in combination. Systematic research by …
Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical …
It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …
variation among patients. They are not intended to supplant physician judgment with respect …
Advances in leishmaniasis
HW Murray, JD Berman, CR Davies, NG Saravia - The Lancet, 2005 - thelancet.com
Governed by parasite and host factors and immunoinflammatory responses, the clinical
spectrum of leishmaniasis encompasses subclinical (inapparent), localised (skin lesions) …
spectrum of leishmaniasis encompasses subclinical (inapparent), localised (skin lesions) …
Drug resistance in leishmaniasis
Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is
caused by over 15 different species of the protozoan parasite genus Leishmania. There are …
caused by over 15 different species of the protozoan parasite genus Leishmania. There are …
An update on pharmacotherapy for leishmaniasis
S Sundar, J Chakravarty - Expert opinion on pharmacotherapy, 2015 - Taylor & Francis
Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …
The relationship between leishmaniasis and AIDS: the second 10 years
J Alvar, P Aparicio, A Aseffa, M Den Boer… - Clinical microbiology …, 2008 - Am Soc Microbiol
To date, most Leishmania and human immunodeficiency virus (HIV) coinfection cases
reported to WHO come from Southern Europe. Up to the year 2001, nearly 2,000 cases of …
reported to WHO come from Southern Europe. Up to the year 2001, nearly 2,000 cases of …
Current and emerging medications for the treatment of leishmaniasis
J Chakravarty, S Sundar - Expert opinion on pharmacotherapy, 2019 - Taylor & Francis
Introduction: Leishmaniasis is a vector-borne neglected tropical disease which manifests as
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …
Use of antimony in the treatment of leishmaniasis: current status and future directions
In the recent past the standard treatment of kala‐azar involved the use of pentavalent
antimonials Sb (V). Because of progressive rise in treatment failure to Sb (V) was limited its …
antimonials Sb (V). Because of progressive rise in treatment failure to Sb (V) was limited its …
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance
Abstract Background. Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is
currently the first-line therapy in the VL elimination program of the Indian subcontinent …
currently the first-line therapy in the VL elimination program of the Indian subcontinent …